Placenta growth factor (PlGF) belongs to the family of vascular endothelial growth factors (VEGFs). It binds to the flt-1 VEGF receptor but not to the KDR/flk-1 receptor which is thought to mediate most of the angiogenic and proliferative effects of VEGF. Three PlGF isoforms are produced by alternative splicing. PlGF-1 and PlGF-3 differ from PlGF-2 since they lack the exon 6 encoded peptide which bestows upon PlGF-2 its heparin binding properties. Cross-linking experiments revealed that 
, was also inhibited by a synthetic peptide derived from exon 7 of PlGF. These observations indicate that the peptides encoded by these exons probably participate in the formation of the domain which mediates the binding of PlGF-2 to these receptors. We have also determined, using chemically modified heparin species, that the presence of sulfate moieties on the glucosamine-O-6 and on the iduronic acid-O-2 groups of heparin was required for the potentiation of 125 I-PlGF-2 binding to these receptors. To determine if PlGF-2 is able to induce biological responses that are not induced by PlGF-1, we compared the effects of PlGF-1 and PlGF-2 on the migration and proliferation of endothelial cells. Both PlGF forms induced migration of endothelial cells. However, there was no quantitative difference between the response to PlGF-2 and the response to PlGF-1. Furthermore, neither PlGF-1 nor PlGF-2 had any effect upon the proliferation of the endothelial cells.
Placenta growth factor (PlGF) 1 was originally described as a placenta produced homodimeric protein that shares substantial structural similarity with vascular endothelial growth factor (VEGF) (1) . Three PlGF forms are produced as a result of alternative splicing (2, 3) . PlGF-2 differs from the other two PlGF forms as it is the only form containing the 21 basic amino acids encoded by exon 6. These 21 amino acids confer on PlGF-2 a heparin binding ability that is lacking in the other PlGF forms (4) . The various forms of VEGF are mitogenic factors for endothelial cells in vitro and important regulators of angiogenesis and blood vessel permeability in vivo (5) . All VEGF isoforms bind to the tyrosine kinase receptors flt-1 (6) and KDR/ flk-1 (7) and respond to VEGF binding by the activation of phosphorylation cascades (8 -11) . The binding of VEGF to KDR/flk-1 is correlated to the induction of angiogenesis and endothelial cell proliferation (12, 13) . In contrast the activation of flt-1 does not seem to result in the induction of cell proliferation but seems to enhance cell migration (13) (14) (15) . Both receptors have also been shown to play pivotal roles in embryonic vasculogenesis (16, 17) . PlGF-1 and PlGF-2 do not interact with KDR/flk-1 but are able to bind to flt-1 (18) . PLGFs induce the migration of cells that express flt-1 receptors (14) but there is disagreement regarding other biological activities. It was reported that PlGF-1 and PlGF-2 cannot induce angiogenesis, endothelial cell proliferation, or blood vessel permeabilization on their own, but that they can potentiate strongly the effect of VEGF on blood vessel permeabilization, and to a lesser extent the mitogenic effect of VEGF (18) . However, other reports indicate that both PlGF-1 and PlGF-2 can induce proliferation of endothelial cells, angiogenesis, and permeabilization of blood vessels, and that PlGF-1 may be less active than PlGF-2 (19, 20) . It was also reported that PlGF-1 can form active heterodimers with VEGF, and these heterodimers are almost as angiogenic as VEGF itself (21) . VEGF/PlGF heterodimers bind to KDR/flk-1, and induce proliferation of endothelial cells almost as efficiently as VEGF (21) . The 121-amino acid form of VEGF (VEGF 121 ) lacks a heparin binding ability, while the 165-amino acid form, VEGF 165 , binds to heparin and heparan sulfate. The heparin binding ability is conferred on VEGF 165 by the exon 7 encoded, 44-amino acid long peptide, which is absent in VEGF 121 (5) . We have recently reported that endothelial cells, as well as other cell types, express in addition to the KDR/flk-1 and flt-1 receptors novel receptors that bind VEGF 165 but not VEGF 121 (22, 23) . These VEGF 165 -specific receptors have been recently shown by direct amino acid sequencing to be the products of the neuropilin-1 gene (24) . Neuropilin-1 has been previously identified as a receptor for the semaphorin/collapsin family proteins which play an important role in the guidance of growing axons (24 -26) . We show here that these receptors also bind PlGF-2 in a heparin-dependent manner, but do not bind PlGF-1. 165 and VEGF 121 were purified from Sf9 insect cells as described previously (27, 28) . PlGF-2 baculoviruses were produced as described (19) . Anti-PlGF antibodies were made against a 6 X His-tagged peptide containing amino acids 22-151 of the mature PlGF-1 protein. This peptide was produced in Escherichia coli, purified by nickel affinity chromatography, and used to immunize rabbits by standard procedures. DifQuick was purchased from Baxter. Heparinase-I was kindly given by Dr. J. Zimermann (Ibex Technologies, Montreal, Canada). S-Sepharose fast flow resin was from Pharmacia Biotech. Na 125 I was obtained from NEN Life Science Products Inc. Disuccinimidyl suberate (DSS) was from Pierce. The C8 brownlee reverse phase column was from Applied Biosystems. Recombinant PlGF-1 was bought from R & D Systems. Intestinal mucosaderived heparin and standard chemicals were from Sigma. Tissue culture plasticware was bought from Nunc. Tissue culture media, sera, and cell culture supplements were from Beth-Haemek Biological Industries, Israel. Synthetic peptides were produced and purified by reverse phase HPLC in the laboratory Dr. Fridkin from the Weizmann Institute of Science, Israel. Peptide 6 (pp6) contained amino acids 142-157 derived from exon 6 of PlGF while peptide-7 (pp7) contained the exon 7 encoded 8 C-terminal amino acids of PlGF.
EXPERIMENTAL PROCEDURES

Materials-Human recombinant VEGF
Production and Purification of PlGF-2-Baculoviruses containing the full-length cDNA of human PlGF-2 were used to infect Sf9 insect cells as described previously (27) . The conditioned medium contained approximately 0.2 mg of PlGF-2/liter. Conditioned medium from the cells was loaded on a cation exchange S-Sepharose fast flow resin at a flow rate of 2 ml/min. The column was washed with 25 ml of wash buffer (25 mM NaP i , pH 6.0, 0.3 M NaCl). PlGF-2 was eluted with elution buffer (10 mM Tris-HCl pH 7.2, 1.1 M NaCl). The fraction containing PlGF-2 was pooled and loaded on a C-8 HPLC reverse phase column, and eluted with an acetonitrile gradient. PlGF-2 eluted from the column at 45% acetonitrile. Excess acetonitrile was evaporated and the PlGF-2 stored at Ϫ70°C.
Iodination of PlGF-2-Iodination of PlGF-2 (3 g of PlGF/iodination) was done using the chloramine-T method essentially as described for VEGF 165 (29) . A S-Sepharose fast flow column (0.1 ml bed volume) was pre-equilibrated with wash buffer containing 25 mM NaP i , pH 6.0, 0.2 M NaCl, and 0.05 mg/ml lactoglobulin.
125 I-PlGF-2 was separated from free 125 I using this column. Bound 125 I-PlGF-2 was eluted with elution buffer containing 10 mM Tris-HCl, pH 7.2, 1 M NaCl, and 0.05 mg/ml lactoglobulin. The iodinated material was immediately used or frozen in liquid nitrogen. The specific activity varied from 4 ϫ 10 4 to 1.4 ϫ 10 5 cpm/ng. Migration Assays-Scratch assays were performed as described (30) . Briefly, monolayers of confluent HUVEC cells were wounded with a razor blade. After wounding the culture was washed with growth medium and growth factors were added. The cells were incubated overnight at 37°C in a humidified incubator. The cells were stained using DifQuick and the number of cells that had migrated into the wounded area counted. Boyden chamber assays were also done as described previously (31) . Briefly, collagen IV (5 mg) was dried on a polycarbonated filter (PVP free, Nucleopore). Fibroblast conditioned medium (obtained from confluent NIH-3T3 cells cultured in serum free Dulbecco's modified Eagle's medium) was used as a positive control. Endothelial cells were harvested by brief exposure to 1 mM EDTA, washed with Dulbecco's modified Eagle's medium containing 0.1% bovine serum albumin, and added to the Boyden chamber (200,000 cells/chamber). The chambers are incubated in a humidified incubator at 37°C in 5% CO 2 , 95% air atmosphere for 6 h. Cells which have traversed and attached to the lower surface of the filter, were stained with DifQuick and counted.
Preparation of Modified Heparins-Synthesis of modified heparins was performed as described (32) . A completely O-2-desulfated heparin was produced from a partial O-2 desulfated heparin, which was again treated with 0.1 M NaOH and freeze dried. The regioselective O-6-desulfated heparin (XV) was synthesized by heating the heparin pyridinium salt for 24 h at 90°C in dimethylformamide. The product was resulfated as described (33) . The completely O-6-desulfated product (XIII) was produced like (XV) but the pyridinium salt of (XV) was used as product (32) .
The heparin derivatives were characterized by 13 C NMR spectroscopy and molecular weight determination. The 13 C NMR spectra were measured on a Bruker DPX-300 spectrometer as long time FT-NMR spectra with more than 30,000 scans at 75 MHz. The signal of the acetyl group carbon was used as internal standard, otherwise methanol was added if the derivative had no acetyl groups. The signals were identified as described (33) (34) (35) . The quantification of the different sulfate groups was done as described (34) . The molecular weight was measured on a Biosil SEC 125 HPLC column which was calibrated with keratan sulfates of defined molecular weight (a gift by Prof. Stuhlsatz, RWTH Aachen). A buffer containing 0.05 M Na 2 HPO 4 and NaH 2 PO 4 , pH 5.8, was used. The flow was set to 1 ml/min and the samples were detected at 205 nm.
Cell Culture and Proliferation Assays-Endothelial cells (HUVEC and bovine aortic arch-derived endothelial cells) and MDA-MB-231 breast cancer cells were cultured essentially as described previously (23, 36, 37) . Proliferation of HUVEC cells was assayed using a Coulter counter as described previously (36) .
Binding and Cross-linking Experiments-The binding and the crosslinking of
125 I-PlGF-2 and 125 I-VEGF 165 to endothelial cells were done essentially as described previously for the binding and cross-linking of 125 I-VEGF 165 to its receptors (22, 29) .
RESULTS
PlGF-2 Binds to Endothelial Cell Surface Receptors That Do
Not Bind PlGF-1-PlGF is produced in three forms of which one (PlGF-2) binds to heparin while PlGF-1 and PlGF-3 do not bind to heparin (3, 4) . To determine if PlGF-2 differs from PlGF-1 in the range of receptors which it recognizes on endothelial cells we have produced recombinant PlGF-2 in insect cells using the baculovirus system, and purified it to apparent homogeneity. The recombinant PlGF-2 was iodinated ( Fig. 1 ) and bound to human umbilical vein-derived endothelial cells (HUVEC cells) in the presence of increasing concentrations of heparin. Bound 125 I-PlGF-2 was subsequently covalently crosslinked to the cells using DSS, and cross-linked complexes were visualized following gel electrophoresis of cell lysates and autoradiography (Fig. 2) . No high molecular weight cross-linked complexes could be observed when the binding of 125 I-PlGF-2 was done in the absence of heparin (Fig. 2, lane 1) . However, two cross-linked complexes of ϳ130 and ϳ150 were detected when 1 g/ml heparin was included in the binding reaction (Fig. 2, lane 3) . When higher concentrations of heparin were added to the binding reaction the formation of the cross-linked complex was progressively inhibited (Fig. 2) . The endogenous cell surface heparan sulfates of the HUVEC cells were not good substitutes for the exogenous heparin. Even when high 125 IPlGF-2 concentrations (25 ng/ml) were bound to the cells in the absence of heparin no formation of cross-linked complexes could be observed (data not shown).
When 125 I-VEGF 165 is bound and cross-linked to HUVEC cells three cross-linked complexes are formed (29) . The larger of these complexes has an apparent mass of ϳ225 kDa and is immunoprecipitated by antibodies directed against KDR/flk-1 (Fig. 4 , lane 5) (22) . The two smaller complexes contain VEGF 165 -specific receptors not recognized by VEGF 121 (22) . The apparent mass of the complex formed following binding of 125 I-PlGF-2 was chromatographed on a 12% SDS-polyacrylamide electrophoresis gel under nonreducing conditions. Shown is an autoradiogram of the gel.
125 I-PlGF-2 to HUVEC cells was similar to mass of that of the complexes formed between VEGF 165 and the VEGF 165 -specific receptors of the endothelial cells (22) . We have therefore tested the ability of the various VEGF and PlGF splice forms to compete with 125 I-PlGF-2 for binding to these receptors. Only VEGF 165 and PlGF-2 inhibited the binding of 125 I-PlGF-2 to these receptors while VEGF 121 did not (Fig. 3) . PlGF-1 inhibited the binding of 125 I-PlGF-2 slightly under the conditions of the experiment (200-fold excess of PlGF-1). It therefore seems that the affinity of PlGF-1 for these receptors is much lower than that of PlGF-2 although not completely negligible (Fig. 3,  lane 4) . When 125 I-PlGF-1 was cross-linked to endothelial cells no cross-linked complexes were formed indicating again that the affinity of PlGF-1 to these receptors is probably much lower than that of PlGF-2 (data not shown). These results were confirmed in a reciprocal experiment in which 125 I-PlGF-2 also recognized and bound to the VEGF 165 -specific receptors of MDA-MB-231 breast cancer cells (23) . VEGF 165 competed with 125 I-PlGF-2 for binding to these receptors while PlGF-1 did not (data not shown). It was recently found that the VEGF 165 -specific receptors of the MDA-MB-231 cells are encoded by the neuropilin-1 gene which is also expressed in endothelial cells (24) . These results suggest that PlGF-2 is able to bind to the neuropilin-1 receptor.
Synthetic Peptides Containing Amino Acid Sequences Derived from Exons 6 and 7 of PlGF-2 Inhibit PlGF-2 Binding-
The presence of exon 6 in PlGF-2 is required for the heparin binding ability of PlGF-2 and for its ability to bind to neuropilin-1 receptors. The VEGF exon that bestow on VEGF 165 the ability to bind to neuropilin-1 and to heparin is exon 7 (22, 23) . Exon 6 of PlGF-2 contains a dense cluster of basic amino acids and has a relatively low overall similarity to exon 7 of VEGF (15.2% overall identity). However, when the N-terminal half of VEGF exon 7 is aligned with exon 6 of PlGF a higher homology (29% identity) is revealed. When a synthetic peptide (pp6) corresponding to the first 15 amino acids encoded by exon 6 of PlGF (4) (Fig. 4,  lanes 4 and 8) , which is seen in cross-linking experiments as a ϳ225 kDa labeled complex (Fig. 4 , lane 5) (22) .
Exon 7 of PlGF is expressed in all of the three PlGF isoforms. Interestingly, a peptide containing the 8 amino acids of exon 7 of PlGF (pp7) was also able to inhibit the binding of 125 I-PlGF-2 to the neuropilin-1-encoded receptors of the HUVEC cells (Fig.  4, lane 3) . This peptide inhibited the binding of 125 I-VEGF 165 to these receptors by about 50% (based on PhosphorImager analysis), but the inhibition was not accompanied by significant inhibition of 125 I-VEGF 165 binding to the KDR receptor (based on PhosphorImager analysis that took into account the decrease in the nonspecific background labeling resulting from the presence of this peptide) (Fig. 4, lane 7) . In contrast, two different peptides derived from unrelated regions of PlGF failed to inhibit the binding of 125 I-PlGF-2 at similar concentrations (data not shown).
Sulfation of Glucosamine-O-6 and Iduronic Acid-O-2 Groups of Heparin Is Required for Potentiation of PlGF-2 Binding to Its
Receptors-The binding of 125 I-PlGF-2 to the receptors of HU-VEC cells seems to depend on the presence of heparin (Fig. 2) . 125 I-PlGF-2 binding to HUVEC cells was performed in the presence of oversulfated heparin (Fig. 5, lane 5) or in the presence of desulfated heparin (Fig. 5, lane 6 Chemically modified heparin species were used to determine if the potentiating effect of heparin depends upon specific sulfated groups. The content of sulfate moieties at specific substituted side groups of heparin had been changed in these modified heparins as detailed in Table I . A heparin in which all N-sulfate groups of the glucosamine were exchanged by acetyl groups (Table I, . At the end of the incubation the cells were washed with cold phosphate-buffered saline, and the bound 125 I-PlGF-2 was cross-linked to cell surface receptors using DSS as described under "Experimental Procedure." The cells were lysed, and aliquots were separated on a 6% SDS-polyacrylamide electrophoresis gel under reducing conditions. 125 I-PlGF-2 receptor complexes were visualized using autoradiography. which only 47% of the glucosamine-O-6 groups are sulfated (as compared with the 84% in native heparin) (Fig. 6, lane 4) . In this heparin species (Table I, XII) the percentage of sulfated iduronic acid O-2 groups is almost normal (down to 51% from 63% in native heparin). The decrease in binding can therefore be attributed in this case mainly to a decrease in the content of sulfated glucosamine-O-6 groups. Nevertheless, this heparin species also contains 1.1% of sulfated glucosamine-O-3 groups as compared with 5.2% sulfated glucosamine-O-3 groups in native heparin (Table I, XII) . To exclude an effect of sulfated glucosamine-O-3 groups, we have conducted an experiment in which we have used a heparin containing no sulfates on glucosamine-O-3 but almost normal sulfation levels in all the other positions (( Table I, XVIII) . This heparin species supported 125 IPlGF-2 binding as well as native heparin indicating that glucosamine-O-3 sulfation is not required (data not shown). We have also conducted an additional experiment in which 125 IPlGF-2 was bound to the cells in the presence of a modified heparin containing normal levels of sulfated iduronic acid-O-2 and glucosamine-O-3 groups but only 25% of sulfated glucosamine-O-6 groups (Table I, XV). No binding of 125 I-PlGF-2 could be seen in the presence of this heparin, indicating that glucosamine-O-6 sulfate groups are indeed required to support 125 IPlGF-2 binding (Fig. 6, lane 8) . Taken 3 and 7) . At the end of the incubation the cells were washed with cold phosphate-buffered saline, and the bound 125 I-PlGF-2 was cross-linked to cell surface receptors using DSS. The cells were subsequently lysed and 125 I-PlGF-2 receptor containing complexes visualized as described under Fig. 2 .
FIG. 5. Undersulfated heparin does not support
125 I-PlGF-2 binding to neuropilin. HUVEC cells were grown to subconfluence in 10-cm dishes. The cells were incubated in the absence (lanes 1 and 2) or presence (lanes 3-6) of 0.05 units/ml heparinase-I at 37°C for 1 h. The cells were washed with cold phosphate-buffered saline and incubated with 5 ng/ml 125 I-PlGF-2 in the in the absence of heparin (lanes 1 and 3) or in the presence of various heparins (1 g/ml): native heparin (lanes 2 and 4), oversulfated heparin (Table I , III) (lane 5), or de-sulfated heparin (Table I , I) (lane 6). At the end of the incubation the cells were washed with cold phosphate-buffered saline, bound 125 I-PlGF-2 was cross-linked to cell surface receptors using DSS as described. The cells were subsequently lysed, aliquots were separated on a 6% SDSpolyacrylamide electrophoresis gel under reducing conditions, and 125 I-PlGF-2 receptor containing complexes visualized as described in the legend to Fig. 2 .
TABLE I A list of modified heparins
The degree of substitution by sulfate in percent at each of the sulfated positions of modified heparin derivatives was evaluated by 13 C NMR spectroscopy as previously described (34) 2-11) . At the end of the incubation the cells were washed with cold phosphate-buffered saline, bound 125 I-PlGF-2 was cross-linked to cell surface receptors using DSS as described. The cells were subsequently lysed, aliquots were separated on a 6% SDS-polyacrylamide electophoresis gel under reducing conditions, and 125 IPlGF-2 receptor containing complexes visualized as described in the legend to Fig. 2. for the successful binding of To examine the importance of sulfated iduronic acid-O-2 groups for 125 I-PlGF-2 binding, 125 I-PlGF-2 binding to HUVEC cells was done in the presence of a heparin containing 17% sulfated iduronic acid O-2 groups as compared with 63% in native heparin, but normal levels of other sulfated groups (Table I , XVI). The binding was somewhat reduced when this modified heparin species was used (Fig. 6, lane 9) . The binding of 125 I-PlGF-2 was completely inhibited when the binding was performed in the presence of a heparin species containing no sulfated iduronic acid O-2 groups but normal sulfation levels in all the other positions (Table I, XVII and Fig. 6, lane 11) . These results indicate that the presence of sulfated iduronic acid-O-2 groups, as well as the presence of sulfated glucosamine-O-6 groups on heparin is required for potentiation of 125 I-PlGF-2 binding.
. O-2S is iduronic-O-2-sulfate content, O-6S, O-3S, NS, or N-Ac stand for ␣-D-glucosamine-O-6-sul-
The Binding of PlGF-2 to Neuropilin-1 Receptors of HUVEC Cells Does Not Induce Cell Proliferation and Does Not Modulate
PlGF-induced Cell Migration-In order to find out if the binding of PlGF-2 to neuropilin-1 affects the proliferation of the endothelial cells, we have compared the effects of PlGF-1 and PlGF-2 on the proliferation of HUVEC cells. However, the cells did not proliferate in response to either PlGF-1 or PlGF-2 (Fig.  7A) . Previous studies have indicated that PlGF-2 can potentiate somewhat the mitogenic activity of VEGF 165 (18) . In contrast to VEGF 165 , VEGF 121 does not bind to neuropilin-1 and does not inhibit the binding of PlGF-2 to these receptors (Fig.  3) . However, VEGF 121 binds efficiently and activates the KDR receptor (22, 38) . We have therefore determined if PlGF-2 can modulate the mitogenic effects of VEGF 121 as a result of its neuropilin-1 binding properties. Endothelial cells were stimulated with VEGF 121 in the presence of 1 g/ml heparin and increasing concentrations of either PlGF-1 or PlGF-2. However, neither PlGF-2 nor PlGF-1 were able to modulate the mitogenic response to VEGF 121 (Fig. 7B) . Similar results were obtained when the experiment was done in the absence of heparin (data not shown). These results indicate that the binding of PlGF-2 to neuropilin-1 does not affect the mitogenic response of the endothelial cells (12) .
Migration of cells in response to PlGF is mediated primarily by the activation of the flt-1 receptor (15, 39) . Northern blot experiments indicate that HUVEC cells express limited amounts of flt-1 mRNA (28). We could not detect flt-1 receptors in the HUVEC cells in binding/cross-linking experiments (28) . We have compared the migration of HUVEC cells in response to PlGF-1 and PlGF-2 in the presence of heparin in order to find out if the cells respond better to PlGF-2 because of its neuropilin-1 binding ability. Using the Boyden chamber assay (40), we have found that both PlGF-1 and PlGF-2 induced cell migration. However, the PlGF-1 and PlGF-2 concentrations that were required to induce half-maximal endothelial cell migration were almost identical (Fig. 8) . Similar results were obtained when the migration assays were done in the absence of heparin (data not shown). These observations indicate that the binding of PlGF-2 to neuropilin-1 does not modulate the migratory response of the endothelial cells. The effects of PlGF-2 and PlGF-1 on the organization of the cellular actin and vimentin networks in the endothelial cells were also compared. However, neither PlGF-1 nor PlGF-2 had any significant effects on the organization of the cytoskeleton in the endothelial cells regardless of the presence or absence of heparin (data not shown).
DISCUSSION
The receptor binding properties and biological activities of PlGF-1 and PlGF-2 were compared in the present study. Binding/cross-linking experiments have shown that endothelial cells and MDA-MB-231 breast cancer cells express on their cell surface receptors that bind PlGF-2 in a heparin-dependent manner, but bind PlGF-1 with a much lower affinity if at all. The apparent mass of these receptors was very similar to the apparent mass of the VEGF 165 -specific receptors which are found on the cell surface of these two cell types (22, 23) . VEGF 165 , but not VEGF 121 , inhibited the binding of 125 IPlGF-2 to these receptors. Reciprocal experiments have shown that the binding of 125 I-VEGF 165 to these receptors is completely inhibited by PlGF-2, but not by PlGF-1. The VEGF 165 -specific receptors have been recently found to be the products of the neuropilin-1 gene (24), and our data therefore suggests that neuropilin-1 can also be regarded as a receptor for PlGF-2. It is interesting to note that neuropilin-1 seems to be a receptor for at least five different ligands, collapsin-1/semaphorin III/D, semaphorin-E, semaphorin-IV, VEGF 165 , and PlGF-2 which are active in very different biological processes such as nervous system development, vasculogenesis, and angiogenesis (25, 41) . Evidence indicating that neuropilin-1 may play a role in all of these processes comes from studies with mice targeted for the disruption of the neuropilin-1 gene. These mice had abnormalities in the peripheral nervous system but died in uterus as a result of anomalies in the development of the cardiovascular system (42) .
The binding of PlGF-2 to neuropilin-1 was inhibited by a synthetic peptide (pp6) derived from exon 6 of PlGF-2. Interestingly, this peptide also inhibited the binding of 125 I-VEGF 165 to these receptors and to the KDR receptor of the HUVEC cells. In the case of VEGF 165 there is evidence suggesting that the exon 7-encoded peptide which distinguishes VEGF 165 from VEGF 121 mediates the binding of VEGF 165 to neuropilin-1, because a fusion protein containing this peptide binds directly to neuropilin-1 (23, 24, 43) . It is therefore possible that the pp6 peptide also binds to neuropilin-1 and competes directly with VEGF 165 and PlGF-2 for binding to this receptor. However, the inhibition of 125 I-VEGF 165 binding which is caused by the exon 6-derived synthetic peptide is reminiscent of the inhibition that is observed when cell surface heparan sulfates are removed from the cell surface of the endothelial cells by enzymatic digestion, or when the access of 125 I-VEGF 165 to cell surface heparan sulfates is blocked by competitors such as platelet factor-4 (22, 36, 44) . It is therefore also possible that pp6 may alternatively inhibit the binding of both 125 I-VEGF 165 and 125 I-PlGF-2 to the heparin-like molecules which normally support the binding of these growth factors to neuropilin-1. We have not been able to discriminate between these two possibilities yet and we are currently conducting experiments in order to distinguish between these two possibilities.
Interestingly, a peptide containing the amino acid sequence of exon 7 of PlGF also inhibited the binding of 125 I-PlGF-2 to neuropilin-1 receptors. This peptide does not contain a cluster of positively charged amino acids and is therefore not expected to bind to heparin-like molecules. This result suggests that exon 7 of PlGF-2 participates in the assembly of the functional binding domain via which PlGF-2 binds to neuropilin-1, and indicates that the pp7 peptide probably competes directly with PlGF-2 for binding to neuropilin-1. We have noticed that in the presence of a large excess of PlGF-1 the binding of PlGF-2 to neuropilin-1 is inhibited slightly. It is possible that this marginal interaction is mediated by the exon 7 peptide that is also present in PlGF-1. (28) . Furthermore, HUVEC cells migrate in response to PlGF-1, and the cell migration is probably mediated by flt-1 receptors (14) . Taken together, these observations indicate that HUVEC cells express functional flt-1 receptors in amounts that are not detectable in binding/cross-linking experiments. Potentiation of PlGF-2 binding to flt-1 receptors as a result of PlGF-2 binding to neuropilin-1 should have been translated to a lower ED 50 of PlGF-2 in cell migration assays. However, the PlGF-2 concentrations that induced a half-maximal migratory response were similar to the PlGF-1 concentrations required for a similar response. The binding of PlGF-2 to the neuropilin-1 receptor of the HUVEC cells is strongly potentiated by heparin. Nevertheless, neither the PlGF-2 induced migration of the endothelial cells nor the PlGF-1 induced migration were affected by the inclusion of heparin in the migration assay. Our experiments therefore suggest that the binding of PlGF-2 to neuropilin-1 does not lead to the modulation of PlGF induced migratory responses, and indicates that neuropilin-1 receptors may not be able to associate with flt-1 receptors following PlGF-2 binding.
The effect of both PlGF types on the proliferation of endothelial cells was also tested. In one study PlGF was reported to be inactive as a mitogen for endothelial cells (18) while other studies have produced opposite results (19, 20) . Our results indicate that neither PlGF-2 nor PlGF-1 are able to induce proliferation of HUVEC cells. Furthermore, neither PlGF-1 nor PlGF-2 were able to modulate the mitogenic activity of VEGF 121 . The biological consequences of the interaction of PlGF-2 with neuropilin-1 are therefore unclear, but it is possible that the interaction of PlGF-2 with neuropilin-1 could affect other responses of endothelial cells such as cell-cell interactions or blood vessel organization in vivo.
The binding of VEGF 165 to neuropilin-1 is strongly enhanced by the addition of exogenous heparin (24, 36) . However, some VEGF 165 binding to these receptors can be seen even in the absence of heparin, provided that cell surface heparan sulfates are present (36) . In contrast, we could not detect PlGF-2 binding to these receptors in the absence of exogenous heparin despite the presence of cell surface heparan sulfates. This observation may indicate that the binding of PlGF-2 to these receptors may be enabled in vivo only under conditions in which a source of heparin is available. Activated mast cells produce heparin and can be recruited during tumor development and in inflamed tissues (45, 46) . PlGF is produced in several types of tumors (47, 48) and it is possible that under these conditions the binding of PlGF-2 to these receptors may be potentiated. Alternatively, it is possible that the binding of PlGF-2 to these receptors is potentiated only when cell surfaceassociated proteoglycans carrying heparan sulfate side chains that have a structure which resembles heparin are produced.
To examine what structural determinants of heparin are required to support PlGF-2 binding to neuropilin-1, we have conducted experiments designed to determine whether specific sulfation patterns of heparin are needed to support PlGF-2 binding. Our experiments indicate that in the absence of iduronic acid-O-2 or glucosamine-O-6 sulfated groups heparin loses its ability to potentiate PlGF-2 binding to neuropilin-1. In contrast, the absence of sulfate groups on the amine of glucosamine or on glucosamine-O-3 had no effect on the ability to potentiate PlGF-2 binding. These results indicate that the heparin-mediated potentiation of PlGF-2 binding to neuropilin-1 receptors is not a simple effect of net charge because the amount of sulfated glucosamine-O-6 groups and N-sulfated groups in native heparin is similar, To conclude, we have shown here that PlGF-2 binds to the previously identified VEGF 165 -specific receptors of the endothelial cells while PlGF-1 does not. The binding is strongly affected by heparin and is apparently mediated through a binding site that includes the peptides encoded by exons 6 and 7 of PlGF. However, the biological consequences of the binding of PlGF-2 to these receptors, recently identified as the products of the neuropilin-1 gene, remain unclear (24) . We have not seen that PlGF-2 binding to these receptors modulates PlGF induced cell migration or nor does it affect VEGF 121 induced cell proliferation. However, it is possible that other functions such as the formation of cell-cell contacts between endothelial cells, or the permeabilization of blood vessels in vivo (18) , will be modulated as a result of such interactions. These possibilities are currently under investigation.
